Parameter Group EO EC BF R (mm) Controls 2.0 1.9 2.3 #,$ (1.7–2.6) (1.6–2.6) (1.8–2.8) OA 2.7** 2.8*** 3.2***,## (2.4–3.4) (2.2–3.8) (2.5–4.1) RA 2.6** 2.8** 3.3***,###,$$ (2.1–3.4) (2.1–3.4) (2.7–4.1) A…
Fig. 1 Decreased Cath V (a), increased endostatin (b) and IL-18 (c) in BALF of Besnier-Boeck-Schaumann disease (BBS) patients as compared with healthy volunteers ROC curves for Cath V, endostatin,…
Fig. 1 Serum concentrations of thrombospondin-2 (TSP-2) (a) and of fibroblast growth factor-2 (FGF-2) (b) in non-small cell lung cancer (NSCLC) patients and healthy control subjects We constructed ROC curves…
Rapid progression (n = 54) Slow progression (n = 55) p Age at examination (years) 14.6 ± 7.5 16.5 ± 5.1 NS (0.7–24.0) (7.3–25.0) NS Age at CKD diagnosis (years) 9.9 ± 6.8 5.6 ± 6.1 0.001 (0.01–22.0) (0.1–20.0) Etiology of…
Sarcoidosis Controls p (n = 111) (n = 65) Age (years) 44.8 ± 10.4 43.3 ± 12.4 BMI (kg/m2) 28.2 ± 3.9 26.8 ± 5.6 0.091 FAS 22.9 ± 7.9 17.0 ± 3.3 0.046 MRC 1.3 ± 0.8 1.1 ± 0.3 0.028 OCD 1.6 ± 0.8 1.1 ± 0.3 0.025 Borg’s scale 0.7 ± 1.3…
Alleles Exposed n (%) Controls n (%) OR (95 %CI) p χ2 XPD Lys 63 (63 %) 106 (77 %) Ref. Gln 37 (37 %) 32 (23 %) 1.94 (1.10–3.43) 0.015 – XPC Lys…
Fig. 1 Clinical characteristics of patients with Hashimoto’s thyroiditis 3.2 Physical Examination and Ultrasound The most frequent finding in HT children was a firm thyroid gland on palpation: in 44…
© Springer International Publishing Switzerland 2014Mieczyslaw Pokorski (ed.)Lung Cancer and Autoimmune DisordersAdvances in Experimental Medicine and Biology83310.1007/5584_2014_17 The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis D. Boruczkowski1 ,…
Patients rs1800734 Patients rs2303425 Controls rs1800734 Control rs2303425 Total sample (n) 422 422 511 486 Gender Male n (%) 322 (76) 324 (77) 287 (56) 270 (56) Female n…
